The report noted a strong quarterly dividend history at Gilead Sciences Inc, and favorable long-term multi-year growth rates in key fundamental data points. The annualized dividend paid by Gilead ...

Shares of Gilead Sciences (NASDAQ: GILD) were jumping 7.9% higher on Wednesday at 11:34 a.m. The solid gain came after the big biotech company announced its 2024 fourth-quarter and full-year ...

Gilead Sciences is rated a Strong Buy due to strong Q4 2024 results, a robust HIV franchise, and an imminent lenacapavir commercialization by summer 2025. Lenacapavir PrEP regimen, with 100% ...